Disclosures for "Pre-existing Lambert-Eaton Myasthenic Syndrome and Scleroderma in a Patient with Neuroendocrine Tumor undergoing Immune Checkpoint Inhibitor Cancer Immunotherapy")
-
Dr. Vorasoot has nothing to disclose.
-
Dr. Halfdanarson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TerSera. Dr. Halfdanarson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Terumo. The institution of Dr. Halfdanarson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. The institution of Dr. Halfdanarson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Advanced Accelerator Applications. The institution of Dr. Halfdanarson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Isotopen Technologien Muenchen (ITM). The institution of Dr. Halfdanarson has received research support from Advanced Accelerator Applications. The institution of Dr. Halfdanarson has received research support from Thermo-Fisher Scientific. The institution of Dr. Halfdanarson has received research support from Camurus.
-
Dr. Madigan has nothing to disclose.
-
Dr. Thanarajasingam has nothing to disclose.
-
The institution of Dr. Zekeridou has received research support from Roche/Genentech. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care.